Nonmalignant Hematology

Expert faculty review and share their insights and perspectives on key findings in nonmalignant hematologic disorders presented at the 2020 ASH Annual Meeting.

Share

Program Content

Activities

  • Expert Analysis
    Key Studies in Nonmalignant Hematology: Independent Conference Coverage of ASH 2020
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 11, 2021

    Expires: February 10, 2022

  • ClinicalThought
    Nonmalignant Hematologic Disorders at ASH 2020: Our Choices for Most Notable Studies
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 24, 2021

    Expires: February 23, 2022

  • Podcast
    Expert Insights on Key Data From ASH 2020 on Nonmalignant Hematologic Disorders
    Conference Coverage
    Podcast Episodes
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 10, 2021

    Expires: February 09, 2022

Activities

Ph I/II: Rilzabrutinib in ITP
Phase I/II Trial of BTK Inhibitor Rilzabrutinib (PRN1008) for Heavily Pretreated Patients With Immune Thrombocytopenia
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2020

Expires: December 15, 2021

ROCKstar
ROCKstar Phase II Trial of Daily or Twice-Daily Belumosudil (KD025) in Previously Treated Patients With Chronic GVHD
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2020

Expires: December 13, 2021

Itacitinib in GVHD
GRAVITAS-119: Phase I Study of Itacitinib Plus Calcineurin Inhibitors as Prophylaxis for GVHD
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2020

Expires: December 17, 2021

Baricitinib in GVHD
Phase I/II Study of JAK1/2 Inhibitor Baricitinib in Refractory Chronic GVHD
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2020

Expires: December 16, 2021

BELIEVE: HRQoL Analysis
BELIEVE: HRQoL Outcomes for Patients With Transfusion-Dependent β-Thalassemia Treated With Luspatercept
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2020

Expires: December 13, 2021

CLIMB THAL-111/SCD-121
CLIMB THAL-111/SCD-121: Phase I/II Studies of CTX001 for Transfusion-Dependent β-Thalassemia and Sickle Cell Disease
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2020

Expires: December 15, 2021

Mitapivat Phase I in SCD
Phase I Dose-Escalation Study of Mitapivat (AG-348) in Patients With Sickle Cell Disease
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2020

Expires: December 15, 2021

REACH3
REACH3: Phase III Trial of Ruxolitinib vs Best Available Therapy in Steroid-Refractory/Dependent, Chronic GVHD
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2020

Expires: December 08, 2021

ITP: 1L MMF + Steroids
FLIGHT: First-line Mycophenolate + Steroids vs Standard Steroid Treatment in Patients With Newly Diagnosed Immune Thrombocytopenia Purpura
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2020

HOPE-B: AMT-061 in HEMB
Phase III HOPE-B: Etranacogene Dezaparvovec Gene Therapy in Adults With Severe or Moderately Severe Hemophilia B
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2020

Expires: December 09, 2021

Provided by

ProCE Banner

Supporters

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology